Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say

Core Insights - Pacific Biosciences of California (PACB) reported a revenue of $37.15 million for the quarter ended March 2025, reflecting a decrease of 4.3$0.15, an improvement from -$0.26 in the same quarter last year, and surpassed the consensus EPS estimate of -$0.19 by 21.05% [1] Revenue Breakdown - Revenue from Product-Instrument was $11 million, falling short of the estimated$12.21 million, marking a significant decline of 42.1% year-over-year [4] - Revenue from Product reached $31.11 million, slightly above the estimated$30.90 million [4] - Revenue from Service and other sources was $6.04 million, exceeding the estimated$4.97 million, representing a substantial increase of 58.9% year-over-year [4] - Revenue from Product-Consumable was $20.10 million, surpassing the average estimate of$18.69 million, with a year-over-year growth of 25.6% [4] Stock Performance - Over the past month, shares of Pacific Biosciences have declined by 22.1%, contrasting with the Zacks S&P 500 composite's increase of 11.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]